论文部分内容阅读
Objective: Pseudobulbar paralysis caused by ischemic stroke(PBP-IS)should be an urgent problem to be solved among the diseases of the nervous system.So far,modern medicine has not find an effective way to tackle this problem.Several studies suggest acupoint-injection may be applied to the treatment of pseudobulbar paralysis(PBP).However,current evidence is not enough to prove its efficacy.Therefore,this pilot study was desgined to certificate the feasibility and validity of Xingnaojing acupoint-injection at(XNJ-AI)Fengchi(GB20)for treatment of pseudobulbar paralysis caused by ischemic stroke(PBP-IS).Methods: This study was an assessor-blinded,two-parallel-group,randomized controlled trial.Participants with(PBP-IS)was recruited and randomly divided into two groups.Participants in the controll group received the oral aspirin(one 100mg tablet once a day for two weeks).In addition to the oral aspirin,patients in the treatment group received Xingnaojing acupoint-injection(XNJ-AI)at Fengchi(GB20)(once a day for two weeks).Measures was taken before and after treatments.The primary outcome was assessed by the Kubota water experiment.The secondary outcome was to measure the TXB2and 6-keto-PGF1a.Results: We observed a significantly greater improvement in swallowing function(P<0.05),and an obvious drop in the TXB2 values(P<0.05)with a remarkable rise in the 6-keto-PGF1a values(P<0.05).Conclusion: XNJ-AI at GB20 may improve the patients' swallowing function and balance the TXB2and 6-keto-PGF1a.